CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS OF THE USE OF REBAMIPIDE IN DISEASES OF THE GASTROINTESTINAL TRACT LITERATURE REVIEW
https://doi.org/10.21518/2079-701X-2016-19-88-95
Abstract
NSAID-induced lesions of the gastrointestinal tract gained wide spread in the recent decade. Their range includes lesion of the esophagus, syndrome of dyspepsia, gastropathy and enteropathy. Diagnosis establishment of enteropathy is complicated and became possible after introduction of the capsule endoscopy. PPI are used for treatment of gastropathy, but they are not effective for treating enteropathy. Cytoprotective prostaglandins play the key role in the development of NSAID lesions of the gastrointestinal tract. Synthetic analogues of prostaglandins of misoprostol type possess cytoprotective action, but cause a significant number of adverse events. Rebamipide, a new gastroprotective agent in Russia stimulates production of endogenous prostaglandins. This drug proved its efficacy during the clinical trials performed according to the standards of the evidence-based medicine.
About the Authors
V. I. SIMANENKOV
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
MD, Prof.
Saint-Petersburg
E. A. LUTAENKO
Mechnikov North-Western State Medical University
Russian Federation
Russian Federation
PhD in medicine
Saint-Petersburg
A. A. NIKOGOSYAN
Mechnikov North-Western State Medical University
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. Terano A, Arakawa T, Sugiyama T. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, doubleblind, placebo-controlled trial.. J Gastroenterol, 2007, 42: 690-693.
2. Han X, Jiang K, Wang B. Effect of Rebamipide on the Premalignant Progression of Chronic Gastritis: A Randomized Controlled Study. Clin Drug Investig, 2015 Oct, 35(10): 665- 73.
3. Endo H, Hosono K, Inamori M. Characteristics of small bowel injury in symptomatic chronic low-dose aspirin users: the experience of two medical centers in capsule endoscopy. J Gastroenterol, 2009, 44: 544-549.
4. Endo H, Higurashi T, Hosono K. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot randomized controlled study .J Gastroenterol, 2011, 46: 894-905.
5. Fellows IW, Clarke JMF, Roberts PF. Nonsteroidal anti-inflammatory drug-induced jejunal and colonic diaphragm disease: a report oftwo cases. Gut, 1992, 33: 1424-1426.
6. Tozawa K, Oshima T, Okugawa T. A Randomized, Double-Blind, Placebo-Controlled Study of Rebamipide for Gastric Mucosal Injury Taking Aspirin With or Without Clopidogrel. Dig. Dis. Sci., 2014, 59: 1885-1890.
7. Mizukami K, Murakami K, Abe T. Aspirininduced small bowel injuries and the preventive effect of rebamipide. World J Gastroenterol, 2011 December 14, 17(46): 5117-5122.
8. Kyung Hwa Lee, Jee-Yeon Kim. Protective Effect of Rebamipide Against Helicobacter pylori- CagA-Induced Effects on Gastric Epithelial Cells. Dig. Dis. Sci.. 2011, 56: 441-448.
9. Masahiro Hasegawa , Noriyuki Horiki. Theefficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor- related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol, 2013, 23: 1172-1178.
10. Takayama M, Matsui Sh. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcer. World J Gastroenterol, 2013 September 14, 19(34): 5706-5712.
11. Koyama N, Sasabe H and Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica, 2002, 327
12. Genta RM. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther, 2003, 18(Suppl. 1): 8-13.
13. Matsumoto S, Tsuji K, Shirahama S. Rebamipide enema therapy for left-sided ischemic colitis patients accompanied by ulcers: Open label study. World J Gastroenterol, 2008 July 7, 14(25): 4059-4064.
14. Zhang Sh, Qing Q, Bai Y. Rebamipide Helps Defend Against Nonsteroidal Anti- Inflammatory Drugs Induced Gastroenteropathy: A Systematic Review and Meta-Analysis. Dig. Dis. Sci., 2013, 58: 1991-2000.
15. Fujiwara Sh, Morita Y, Toyonaga T. A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol, 2011, 46: 595-602.
16. Fujimori Sh, Gudis K and Sakamoto Ch. A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury. Pharmaceuticals, 2010, 3: 1187-1201.
17. Soo Heon Park, Chul Soo Cho. Comparison of Prevention of NSAID-Induces Gastrointestinal Complications by Rebamipide and Misoprostol: A randomised, multicenter, Controlled Trial-STORM STUDY. J. Clin Biochem. Nutr., 2007 March, 40: 148-155.
18. YiqiDu Zhaoshen, Li Xianbao Zhan. Antiinflammatory Effects of Rebamipide According to Helicobacter pylori Status in Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in China-STARS Study. Dig. Dis. Sci., 2008, 53: 2886- 2895.
19. Еремина.Е.Ю. Новые возможности цитопротективной терапии эрозивно-язвенных поражений желудочно-кишечного тракта. Практическая гастроэнтерология, 2015, 16: 1-4.
20. Клинические рекомендации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. Российская Гастро энтерологическая Ассоциация. Доступно по http://www.gastro.ru. Ссылка активна на 10.09.2015.
21. Клинические рекомендации по применению НПВП. Под ред. А.Е. Каратаева. М.: Има Пресс, 2009.
22. Симаненков В.И., Тихонов С.В. Ребамипид – новые возможности гастропротекции. Терапевтический архив, 2015, 12 115-117.
23. Ткач С.М., Балабанцева А.П. Современные подходы к лечению НПВП-энтеропатий. Гастроэнтерология, 2014, 6(80): 37-42.
24. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б., Кукушкин М.Л., Дроздов В.Н., Исаков В.А. Применение нестероидных противовоспалительных препаратов. М.: ИмаПРЕСС, 2009.
Review
For citations:
SIMANENKOV VI, LUTAENKO EA, NIKOGOSYAN AA. CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS OF THE USE OF REBAMIPIDE IN DISEASES OF THE GASTROINTESTINAL TRACT LITERATURE REVIEW. Meditsinskiy sovet = Medical Council. 2016;(19):88-95. (In Russ.) https://doi.org/10.21518/2079-701X-2016-19-88-95
Views:
731
Email this article 